Androgens and prostate cancer risk
2008 (English)In: Baillière's Best Practice & Research. Clinical Endocrinology & Metabolism, ISSN 1521-690X, E-ISSN 1532-1908, Vol. 22, no 4, 601-613 p.Article in journal (Refereed) Published
Androgens have been implicated in prostate tumourigenesis. However, no association between circulating levels of androgens and prostate cancer risk was found in a recent large pooled analysis of prospective studies. A decreased risk of prostate cancer among men treated with finasteride, a 5α-reductase inhibitor which reduces levels of dihydrotestosterone, was observed in the Prostate Cancer Prevention Trial (PCPT), a large clinical trial. In the PCPT, a higher number of high-grade tumours was found in the finasteride group than in the control group; the reason for this finding is still unclear. Treatment of symptoms of late-onset hypogonadism – such as decreased muscle and bone mass and decreased cognition and libido – has become more prevalent with the advent of new forms of administration of testosterone replacement therapy. One small placebo-controlled study showed no increase in incidence of prostate cancer after 6 months of testosterone therapy, but data on the safety of testosterone replacement therapy remain limited.
Place, publisher, year, edition, pages
2008. Vol. 22, no 4, 601-613 p.
prostatic neoplasms, androgens, finasteride, testosterone, late-onset hypogonadism, testosterone replacement therapy
Urology and Nephrology
IdentifiersURN: urn:nbn:se:umu:diva-71464DOI: 10.1016/j.beem.2008.06.002OAI: oai:DiVA.org:umu-71464DiVA: diva2:624116